Margaux Geier

577 total citations
41 papers, 220 citations indexed

About

Margaux Geier is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Margaux Geier has authored 41 papers receiving a total of 220 indexed citations (citations by other indexed papers that have themselves been cited), including 33 papers in Oncology, 32 papers in Pulmonary and Respiratory Medicine and 5 papers in Surgery. Recurrent topics in Margaux Geier's work include Lung Cancer Treatments and Mutations (22 papers), Cancer Immunotherapy and Biomarkers (20 papers) and Lung Cancer Research Studies (14 papers). Margaux Geier is often cited by papers focused on Lung Cancer Treatments and Mutations (22 papers), Cancer Immunotherapy and Biomarkers (20 papers) and Lung Cancer Research Studies (14 papers). Margaux Geier collaborates with scholars based in France, United States and Belgium. Margaux Geier's co-authors include G. Robinet, R. Descourt, R. Corre, Ulrike Schick, Gilles Quéré, C. Chouaïd, François Lucia, R. Lamy, Vincent Bourbonne and H. Léna and has published in prestigious journals such as Journal of Clinical Oncology, Scientific Reports and CHEST Journal.

In The Last Decade

Margaux Geier

35 papers receiving 218 citations

Peers

Countries citing papers authored by Margaux Geier

Since Specialization

Citations

This map shows the geographic impact of Margaux Geier's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Margaux Geier with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Margaux Geier more than expected).

Fields of papers citing papers by Margaux Geier

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Margaux Geier. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Margaux Geier. The network helps show where Margaux Geier may publish in the future.

Co-authorship network of co-authors of Margaux Geier

This figure shows the co-authorship network connecting the top 25 collaborators of Margaux Geier. A scholar is included among the top collaborators of Margaux Geier based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Margaux Geier. Margaux Geier is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	ICARUS-LUNG01: A phase 2 study of datopotomab deruxtecan (Dato-DXd) in patients with previously treated advanced non-small cell lung cancer (NSCLC), with sequential tissue biopsies and biomarkers analysis to predict treatment outcome. 2024 ·Journal of Clinical Oncology ·David Planchard, Nathalie Cozic, Marie Wislez, C. Chouaïd, (unknown), Sophie Cousin, Céline Mascaux, Jacques Cadranel, Margaux Geier, Maria‐Rosa Ghigna, (unknown), Ricardo Zwirtes, Rachel Chiaverelli, (unknown), (unknown), Fernanda Mosele, Fabrice André, Guillaume Montagnac, Barbara Pistilli	6
2	Identification of CT radiomic features robust to acquisition and segmentation variations for improved prediction of radiotherapy-treated lung cancer patient recurrence 2024 ·Scientific Reports ·Thomas Louis, François Lucia, François Cousin, (unknown), Nicolas Jansen, Bernard Duysinx, (unknown), Dimitris Visvikis, (unknown), (unknown), (unknown), Margaux Geier, Pierre‐Yves Salaün, Ulrike Schick, Mathieu Hatt, Philippe Coucke, Pierre Lovinfosse, Roland Hustinx	2
3	Nivolumab plus ipilimumab versus carboplatin-based doublet as first-line treatment for patients with advanced non-small-cell lung cancer aged ≥70 years or with an ECOG performance status of 2 (GFPC 08–2015 ENERGY): a randomised, open-label, phase 3 study 2024 ·The Lancet Respiratory Medicine ·H. Léna, Laurent Greillier, Claire Cropet, Olivier Bylicki, I. Monnet, Clarisse Audigier-Valette, L. Falchero, A. Vergnenègre, (unknown), Margaux Geier, Florian Guisier, S. Hominal, Chrystèle Locher, R. Corre, C. Chouaïd, Charles Ricordel, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown)	5
4	Incidence of venous thromboembolism and association with PD-L1 expression in advanced non-small cell lung cancer patients treated with first-line chemo-immunotherapy 2024 ·Frontiers in Oncology ·(unknown), (unknown), Cécile Tromeur, Françis Couturaud, R. Descourt, Margaux Geier	2
5	Safety and efficacy of second-line metronomic oral vinorelbine-atezolizumab combination in stage IV non-small-cell lung cancer: An open-label phase II trial (VinMetAtezo) 2023 ·Lung Cancer ·A. Vergnenègre, I. Monnet, Charles Ricordel, (unknown), (unknown), Massimo Bernardi, R. Corre, Florian Guisier, S. Hominal, G. Le Garff, Olivier Bylicki, Chrystèle Locher, Margaux Geier, C. Chouaïd, G. Robinet	5
6	Predictors of three-month mortality and severe chemotherapy-related adverse events in patients aged 70 years and older with metastatic non-small-cell lung cancer: A secondary analysis of ESOGIA-GFPC-GECP 08–02 study 2023 ·Journal of Geriatric Oncology ·(unknown), (unknown), R. Corre, Laurent Greillier, (unknown), Olivier Bylicki, C. Decroisette, J.B. Auliac, Florian Guisier, Margaux Geier, Charles Ricordel, Maxime Frélaut, Éléna Paillaud, C. Chouaïd, Florence Canouï‐Poitrine	2
7	Pembrolizumab plus pemetrexed-carboplatin combination in first-line treatment of advanced non-squamous non-small cell lung cancer: a multicenter real-life study (CAP29) 2023 ·Translational Lung Cancer Research ·(unknown), Charles Ricordel, R. Corre, (unknown), (unknown), (unknown), (unknown), François Lucia, Vincent Bourbonne, G. Robinet, R. Descourt, (unknown), Gilles Quéré, Margaux Geier	3
8	Multicentric development and evaluation of [18F]FDG PET/CT and CT radiomic models to predict regional and/or distant recurrence in early-stage non-small cell lung cancer treated by stereotactic body radiation therapy 2023 ·European Journal of Nuclear Medicine and Molecular Imaging ·François Lucia, Thomas Louis, François Cousin, Vincent Bourbonne, Dimitris Visvikis, (unknown), Nicolas Jansen, Bernard Duysinx, (unknown), (unknown), (unknown), (unknown), Margaux Geier, Pierre‐Yves Salaün, Ulrike Schick, Mathieu Hatt, (unknown), Roland Hustinx, Pierre Lovinfosse	11
9	Venous thrombotic events and impact on outcomes in patients treated with first-line single-agent pembrolizumab in PD-L1 ≥ 50% advanced non small cell lung cancer 2023 ·Journal of Cancer Research and Clinical Oncology ·H. Doubre, Laurent Greillier, (unknown), Charles Ricordel, Aurélie Swalduz, (unknown), Olivier Bylicki, J.B. Auliac, Florian Guisier, L. Bigay-Gamé, Massimo Bernardi, J. Pinsolle, Karim Amrane, C. Decroisette, R. Descourt, C. Chouaïd, Margaux Geier	2
10	Brigatinib for Pretreated, ALK-Positive, Advanced Non-Small-Cell Lung Cancers: Long-Term Follow-Up and Focus on Post-Brigatinib Lorlatinib Efficacy in the Multicenter, Real-World BrigALK2 Study 2022 ·Cancers ·R. Descourt, M. Pérol, (unknown), David Planchard, B. Mennecier, Marie Wislez, Jacques Cadranel, Alexis B. Cortot, Florian Guisier, Loïck Galland, Pascal Dô, Roland Schött, Éric Dansin, Jennifer Arrondeau, J.B. Auliac, Margaux Geier, C. Chouaïd	5
11	Immune-Checkpoint Inhibitors for Malignant Pleural Mesothelioma: A French, Multicenter, Retrospective Real-World Study 2022 ·Cancers ·Jean‐Baptiste Assié, (unknown), Emmanuel Grolleau, Anthony Canellas, Margaux Geier, (unknown), (unknown), Aldo Renault, Pierre-Alexandre Hauss, (unknown), (unknown), Alexis B. Cortot, Marie Wislez, Clément Gauvain, C. Chouaïd, Arnaud Scherpereel, I. Monnet	11
12	465P Larotracking: Real-life study of locally advanced/metastatic solid tumor treated with larotrectinib in French expanded access program 2022 ·Annals of Oncology ·Armelle Dufresne, Olivier Huillard, Cécile Dalban, Margaux Geier, (unknown), Sylvie Zanetta, (unknown), Bogdan Catargi, (unknown), (unknown), (unknown), (unknown), Esma Saâda, (unknown), (unknown), Élodie Vauléon, (unknown), David Pérol, Jean‐Yves Blay	2
13	937P Incidence and outcomes of EGFR mutated non-small cell lung cancer treated with surgery: EXERPOS GFPC study 2022 ·Annals of Oncology ·J.B. Auliac, (unknown), P. Thomas, (unknown), Olivier Bylicki, (unknown), Aurélie Swalduz, Marie Wislez, Margaux Geier, J. Le Treut, C. Decroisette, (unknown), Jérémy Tricard, (unknown), (unknown), (unknown), (unknown), (unknown), C. Chouaïd, Laurent Greillier	0
14	Multicenter phase II trial of nintedanib plus docetaxel in second-line treatment in advanced non-squamous non-small cell lung cancer patients refractory to first-line platin-based chemotherapy (REFRACT GFPC 02–15 study) 2021 ·Lung Cancer ·J.B. Auliac, I. Monnet, (unknown), Laurent Greillier, Margaux Geier, L. Falchero, G. Le Garff, R. Lamy, Florian Guisier, Charles Ricordel, C. Chouaïd, A. Vergnenègre	3
15	71P Searching for predictive biomarkers of efficacy in small cell lung cancer (SCLC) patients treated with chemotherapy-immunotherapy combination using imaging mass cytometry (the HYPE study) 2021 ·Annals of Oncology ·(unknown), Patrice Hémon, (unknown), G. Robinet, R. Descourt, Gilles Quéré, (unknown), (unknown), (unknown), Ulrike Schick, (unknown), Arnaud Uguen, Margaux Geier	4
16	Vascular Acrosyndromes Associated With Prolonged Tumor Response in Advanced Lung Cancer Patients During Treatment With Antimetabolites: A Report of Two Cases 2021 ·Frontiers in Oncology ·Margaux Geier, (unknown), (unknown), Gilles Quéré, R. Descourt, Divi Cornec, G. Robinet	2
17	A 60-Year-Old Woman With Recurrent Hemoptysis 2020 ·CHEST Journal ·Margaux Geier, (unknown), L. Khatchatourian, (unknown), G. Robinet, Françis Couturaud, (unknown)	0
18	OA15.02 Carboplatin-Etoposide Versus Topotecan as Second-Line Treatment for Sensitive Relapsed Small-Cell Lung Cancer: Phase 3 Trial 2019 ·Journal of Thoracic Oncology ·Nathalie Baize, I. Monnet, Laurent Greillier, Margaux Geier, H. Léna, Henri Janicot, A. Vergnenègre, Jacky Créquit, R. Lamy, J.B. Auliac, J. Le Treut, H. Le Caer, R. Gervais, Éric Dansin, A. Madroszyk, (unknown), (unknown), Roland Schött, Patrick Saulnier, C. Chouaïd	5
19	Real life second-line nivolumab in advanced non-small cell lung cancer: A French observational multicenter study of 259 patients (ABCT-IMMUNOBZH) 2018 ·Margaux Geier, R. Descourt, R. Corre, (unknown), R. Lamy, (unknown), (unknown), (unknown), Gilles Quéré, (unknown), François Montestruc, Françis Couturaud, G. Robinet	5
20	MA08.10 Real-Life Intracerebral Efficacy of Nivolumab in Non-Small Cell Lung Cancer Patients with Brain Metastases 2018 ·Journal of Thoracic Oncology ·Margaux Geier, R. Descourt, R. Corre, (unknown), R. Lamy, (unknown), (unknown), (unknown), Gilles Quéré, Françis Couturaud, G. Robinet	10

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact